Systemic mast cell disease: diagnosis and management
Figure 12.1 Darier’s sign. Blood tests carried out show a normal full blood count, liver function tests, and bone profile (calcium and vitamin D level). Is a skin biopsy necessary…
Hematopoietic cell transplantation for myelofibrosis: who and when?
JAK1/2 inhibitor therapy has potential to improve the pre-HCT performance status by effective control of MF-related symptom burdenSeveral transplant studies have shown the relationship with, or better performance status with,…
Myelodysplastic/myeloproliferative neoplasm overlap syndromes
Figure 14.1 The spectrum of bone marrow failure disorders and other myeloid neoplasms. AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MPN, myeloproliferative neoplasm; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic…
Women and children with myeloproliferative neoplasms – special considerations
Figure 16.1 Diagnostic algorithm for pediatric thrombocytosis. TIBC, total iron-binding capacity; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CBC, complete blood count; MPN, myeloproliferative neoplasm; CML, chronic myeloid leukemia. Secondary…
Management of acute leukemia following myeloproliferative neoplasms
Figure 21.1 Clinical and pathogenetic changes occurring during myeloproliferative disorder progression. MPN, myeloproliferative neoplasm; MPN-BP, MPN blast phase; ET, essential thrombocythemia; PMF, primary myelofibrosis; PV, polcythemia vera; MF, myelofibrosis; LDH,…
Familial myeloproliferative neoplasms – implications for patients and their families
Figure 20.1 Pedigree of family with myeloproliferative neoplasm. Filled symbols indicate affected individuals. The Roman numerals represent generation and the Greek numeral stands for the individual family member. PV, polycythemia…
Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
Figure 10.1 Survival estimates from diagnosis of primary myelofibrosis patients who become intermediate-2 and high-risk International Prognostic Score System (IPSS) with a blast cell count <10% at any time of…
Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
Figure 19.1 Challenging thrombosis scenarios. MPN, myeloproliferative neoplasm; APC, activated protein C resistance. As reviewed in: Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014;40(3):348–58. Adapted from:…
Managing acute vascular events in patients with myeloproliferative neoplasms
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> 18 Managing acute vascular events in patients with myeloproliferative neoplasms David A. Garcia and Bethany T. Samuelson Case 1 A 62-year-old man is referred to hematology…
Conception and pregnancy in myeloproliferative neoplasms
Figure 17.1 Local management protocol. FBC, full blood count; BP, blood pressure; PV, polycythemia vera. There are no controlled studies regarding pregnancy outcome. As such there are no validated predictors…
